Products Categories
CAS No.: | 20830-75-5 |
---|---|
Name: | DIGOXIN |
Article Data: | 11 |
Molecular Structure: | |
Formula: | C41H64O14 |
Molecular Weight: | 780.951 |
Synonyms: | Digitoxin,12b-hydroxy- (6Cl);12b-Hydroxydigitoxin;Cardigox;Cardiogoxin;Cardioxin;Cardixin;Cardoxin;Chloroformic digitalin;Coragoxine;Cordioxil;Davoxin;Digacin;Digomal;Digon;Digosin;Digoxin Nativelle;Digoxine;Dilanacin;Dynamos;Eudigox;Grexin;Homolle's digitalin;Lanacordin;Lanocardin;Lanorale;Lanoxicaps;Lanoxin;Lanoxin PG;Lenoxicaps;Lenoxin;Mapluxin;NSC 95100;Natigoxin;NeoDioxanin;Rougoxin;Stillacor;Toloxin;Vanoxin; |
EINECS: | 244-068-1 |
Density: | 1.36 g/cm3 |
Melting Point: | 248 °C |
Boiling Point: | 931.6 °C at 760 mmHg |
Flash Point: | 278.5 °C |
Solubility: | 46.08mg/L(room temperature) |
Appearance: | White cystalline pwder |
Hazard Symbols: | Moderately toxic.T, T+ |
Risk Codes: | 25-26/27/28 |
Safety: | 22-36/37/39-45 |
Transport Information: | UN 3462 6.1/PG 2 |
PSA: | 203.06000 |
LogP: | 2.21810 |
EPA Extremely Hazardous Substances List. Reported in EPA TSCA Inventory. EPA Genetic Toxicology Program.
The Digoxin with CAS registry number of 20830-75-5 is also known as Cardiogoxin. The IUPAC name is 3-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-3-[(2R,4S,5S,6R)-5-[(2S,4S,5S,6R)-5-[(2S,4S,5S,6R)-4,5-Dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-12,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one. It belongs to product categories of Organics; Biochemistry; Glycosides; Steroidglycosides; Steroids; Sugars; Trisaccharides; Intermediates & Fine Chemicals; Pharmaceuticals; ATPase. Its EINECS registry number is 244-068-1. In addition, the formula is C41H64O14 and the molecular weight is 780.94. This chemical is a white cystalline pwder and should be sealed in cool and dry place away from oxides.
Physical properties about Digoxin are: (1)ACD/LogP: 0.85; (2)# of Rule of 5 Violations: 3; (3)ACD/LogD (pH 5.5): 0.85; (4)ACD/LogD (pH 7.4): 0.85; (5)ACD/BCF (pH 5.5): 2.61; (6)ACD/BCF (pH 7.4): 2.61; (7)ACD/KOC (pH 5.5): 69.21; (8)ACD/KOC (pH 7.4): 69.21; (9)#H bond acceptors: 14; (10)#H bond donors: 6; (11)#Freely Rotating Bonds: 13; (12)Index of Refraction: 1.602; (13)Molar Refractivity: 196.38 cm3; (14)Molar Volume: 572.3 cm3; (15)Surface Tension: 64.5 dyne/cm; (16)Density: 1.36 g/cm3; (17)Flash Point: 278.5 °C; (18)Enthalpy of Vaporization: 153.77 kJ/mol; (19)Boiling Point: 931.6 °C at 760 mmHg.
Preparation of Digoxin: it is extracted from the foxglove plant, digitalis lanata. After fermentation of dry leaves, reactant is extracted by ethanol, chloroform and recrystallized by 70% ethanol to obtain the product.
Uses of Digoxin: it is used to produce 3b,14-dihydroxy-12-oxo-5b,14b-card-20(22)-enolid. The reaction occurs with reagent CrO3 and solvent dimethylformamide for 30 hours. The yield is about 60%. Besides, it is used as cholesterol reagent, tonic and also used in biochemical research.
When you are using this chemical, please be cautious about it. As a chemical, it is very toxic by inhalation, in contact with skin and if swallowed. During using it, wear suitable protective clothing, gloves and eye/face protection. Do not breathe dust. In case of accident or if you feel unwell seek medical advice immediately.
You can still convert the following datas into molecular structure:
1. Canonical SMILES: CC1C(C(CC(O1)OC2C(OC(CC2O)OC3C(OC(CC3O)OC4CCC5(C(C4)CCC6C5CC(C7(C6(CCC7C8=CC(=O)OC8)O)C)O)C)C)C)O)O
2. Isomeric SMILES: C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CC[C@@H]7C8=CC(=O)OC8)O)C)O)C)C)C)O)O
3. InChI: InChI=1S/C41H64O14/c1-19-36(47)28(42)15-34(50-19)54-38-21(3)52-35(17-30(38)44)55-37-20(2)51-33(16-29(37)43)53-24-8-10-39(4)23(13-24)6-7-26-27(39)14-31(45)40(5)25(9-11-41(26,40)48)22-12-32(46)49-18-22/h12,19-21,23-31,33-38,42-45,47-48H,6-11,13-18H2,1-5H3/t19-,20-,21-,23-,24+,25-,26-,27+,28+,29+,30+,31-,33+,34+,35+,36-,37-,38-,39+,40+,41+/m1/s1
4. InChIKey: LTMHDMANZUZIPE-PUGKRICDSA-N
The toxicity data is as follows:
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
cat | LD50 | oral | 200ug/kg (0.2mg/kg) | Archives Internationales de Pharmacodynamie et de Therapie. Vol. 159, Pg. 1, 1966. | |
cat | LDLo | intraduodenal | 441ug/kg (0.441mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 20, Pg. 1765, 1970. | |
cat | LDLo | intravenous | 159ug/kg (0.159mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 19, Pg. 657, 1969. | |
cat | LDLo | parenteral | 1470ug/kg (1.47mg/kg) | Acta Poloniae Pharmaceutica. For English translation, see APPFAR. Vol. 34, Pg. 431, 1977. | |
child | TDLo | oral | 54ug/kg (0.054mg/kg) | CARDIAC: PULSE RATE | American Journal of Emergency Medicine. Vol. 4, Pg. 364, 1986. |
child | TDLo | oral | 127ug/kg (0.127mg/kg) | CARDIAC: PULSE RATE | American Family Physician. Vol. 34(1), Pg. 137, 1986. |
dog | LDLo | intravenous | 200ug/kg (0.2mg/kg) | Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales. Vol. 109, Pg. 279, 1932. | |
dog | LDLo | oral | 300ug/kg (0.3mg/kg) | Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales. Vol. 109, Pg. 279, 1932. | |
frog | LD50 | subcutaneous | 2240ng/kg (0.00224mg/kg) | Russian Pharmacology and Toxicology Vol. 53, Pg. 171, 1990. | |
frog | LDLo | parenteral | 1mg/kg (1mg/kg) | Chemical and Pharmaceutical Bulletin. Vol. 11, Pg. 613, 1963. | |
guinea pig | LD50 | intraduodenal | 3200ug/kg (3.2mg/kg) | CARDIAC: CARDIOMYOPATHY INCLUDING INFARCTION CARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION) | Arzneimittel-Forschung. Drug Research. Vol. 21, Pg. 225, 1971. |
guinea pig | LD50 | intramuscular | 630ug/kg (0.63mg/kg) | Drugs in Japan Vol. 6, Pg. 316, 1982. | |
guinea pig | LD50 | intraperitoneal | 800ug/kg (0.8mg/kg) | Oyo Yakuri. Pharmacometrics. Vol. 7, Pg. 373, 1973. | |
guinea pig | LD50 | oral | 3500ug/kg (3.5mg/kg) | Archives Internationales de Pharmacodynamie et de Therapie. Vol. 159, Pg. 1, 1966. | |
guinea pig | LD50 | subcutaneous | 600ug/kg (0.6mg/kg) | CARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION) | Journal of Pharmacy and Pharmacology. Vol. 35, Pg. 580, 1983. |
guinea pig | LDLo | intravenous | 468ug/kg (0.468mg/kg) | BRAIN AND COVERINGS: RECORDINGS FROM SPECIFIC AREAS OF CNS BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD CARDIAC: OTHER CHANGES | Archives Internationales de Pharmacodynamie et de Therapie. Vol. 153, Pg. 436, 1965. |
infant | LDLo | intravenous | 200ug/kg (0.2mg/kg) | CARDIAC: PULSE RATE | Pediatrics. Vol. 77, Pg. 848, 1986. |
infant | TDLo | intravenous | 50ug/kg (0.05mg/kg) | CARDIAC: PULSE RATE | American Family Physician. Vol. 34(1), Pg. 137, 1986. |
man | TDLo | oral | 75ug/kg (0.075mg/kg) | CARDIAC: EKG CHANGES NOT DIAGNOSTIC OF ABOVE CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP | American Journal of Emergency Medicine. Vol. 6, Pg. 465, 1988. |
man | TDLo | oral | 333ug/kg (0.333mg/kg) | SENSE ORGANS AND SPECIAL SENSES: VISUAL FIELD CHANGES: EYE CARDIAC: PULSE RATE | British Medical Journal. Vol. 287, Pg. 392, 1983. |
man | TDLo | unreported | 13ug/kg/4D-I (0.013mg/kg) | BEHAVIORAL: CHANGES IN PSYCHOPHYSIOLOGICAL TESTS VASCULAR: OTHER CHANGES LUNGS, THORAX, OR RESPIRATION: DYSPNEA | American Heart Journal. Vol. 106, Pg. 419, 1983. |
mouse | LD50 | intracrebral | 124ug/kg (0.124mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | Pharmacological Research Communications. Vol. 6, Pg. 417, 1974. |
mouse | LD50 | intraperitoneal | 3964ug/kg (3.964mg/kg) | Chemotherapy Vol. 16, Pg. 371, 1971. | |
mouse | LD50 | intravenous | 7670ug/kg (7.67mg/kg) | Pharmacological Research Communications. Vol. 6, Pg. 417, 1974. | |
mouse | LD50 | oral | 17780ug/kg (17.78mg/kg) | BRAIN AND COVERINGS: RECORDINGS FROM SPECIFIC AREAS OF CNS BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD CARDIAC: OTHER CHANGES | Archives Internationales de Pharmacodynamie et de Therapie. Vol. 153, Pg. 436, 1965. |
mouse | LD50 | subcutaneous | 8150ng/kg (0.00815mg/kg) | Russian Pharmacology and Toxicology Vol. 53, Pg. 171, 1990. | |
mouse | LDLo | parenteral | 2947ug/kg (2.947mg/kg) | Shang-hai I Hsueh. Vol. 4(2), Pg. 32, 1981. | |
pig | LDLo | intraduodenal | 1580ug/kg (1.58mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 20, Pg. 229, 1970. | |
pig | LDLo | intravenous | 230ug/kg (0.23mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 20, Pg. 229, 1970. | |
pigeon | LDLo | intravenous | 337ug/kg (0.337mg/kg) | CARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION) CARDIAC: CHANGE IN RATE GASTROINTESTINAL: NAUSEA OR VOMITING | Archives Internationales de Pharmacodynamie et de Therapie. Vol. 126, Pg. 412, 1960. |
pigeon | LDLo | parenteral | 450ug/kg (0.45mg/kg) | Chemical and Pharmaceutical Bulletin. Vol. 11, Pg. 613, 1963. | |
rabbit | LD50 | intravenous | 3560ug/kg (3.56mg/kg) | Drugs in Japan Vol. 6, Pg. 316, 1982. | |
rat | LD50 | intraperitoneal | 4mg/kg (4mg/kg) | Journal of Drug Research. Vol. 17, Pg. 247, 1987. | |
rat | LD50 | intravenous | 25mg/kg (25mg/kg) | Archives Internationales de Pharmacodynamie et de Therapie. Vol. 155, Pg. 165, 1965. | |
rat | LD50 | oral | 28270ug/kg (28.27mg/kg) | Archives Internationales de Pharmacodynamie et de Therapie. Vol. 164, Pg. 47, 1966. | |
rat | LD50 | subcutaneous | 8900ng/kg (0.0089mg/kg) | Russian Pharmacology and Toxicology Vol. 53, Pg. 171, 1990. | |
rat | LDLo | rectal | 5mg/kg (5mg/kg) | CARDIAC: PULSE RATE | Planta Medica. Vol. 25, Pg. 88, 1974. |
women | TDLo | oral | 100ug/kg (0.1mg/kg) | BEHAVIORAL: ANOREXIA (HUMAN CARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION) GASTROINTESTINAL: NAUSEA OR VOMITING | New Zealand Medical Journal. Vol. 84, Pg. 443, 1976. |
women | TDLo | oral | 165ug/kg/33D- (0.165mg/kg) | BEHAVIORAL: GENERAL ANESTHETIC BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY) | British Medical Journal. Vol. 296, Pg. 1262, 1988. |
women | TDLo | oral | 500ug/kg (0.5mg/kg) | CARDIAC: EKG CHANGES NOT DIAGNOSTIC OF ABOVE CARDIAC: PULSE RATE INCREASE WITHOUT FALL IN BP GASTROINTESTINAL: NAUSEA OR VOMITING | Clinical Toxicology. Vol. 15, Pg. 437, 1979. |